Condition
Variant Angina
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Completed1
Unknown1
Active Not Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03228238Phase 4TerminatedPrimary
ANti-Oxidant in Variant Angina (ANOVA) Trial
NCT06992830Not ApplicableActive Not RecruitingPrimary
Cardioneuroablation for Variant Angina
NCT01674686Phase 4UnknownPrimary
The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
NCT01444885Phase 2CompletedPrimary
Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina
Showing all 4 trials